Results Glibenclamide was detected out.
结果检出格列本脲。
Both micronized glibenclamide and inclusion complex were fairly stable.
微粉化物及包合物均有良好的稳定性。
The pharmacological activity of glibenclamide could potentially affect ER function.
格列本脲的药理学活性可能潜在影响ER的功能。
Now commonly used oral hypoglycemic agents are glucophage, glibenclamide and so on.
目前常用的口服降糖药有双胍类、磺脲类、噻磋烷二酮类等。
The channel is not sensitive to tetraethylammonium but was inhibited by glibenclamide.
该通道对四乙胺不敏感，但可被优降糖所抑制。
OBJECTIVE To establish an HPLC method for determining glibenclamide in Xiaokeping granules.
目的建立测定消渴平颗粒中格列本脲含量的方法。
The solubility results of inclusion complex in water indicated that the solubility of glibenclamide increased by 15 times.
包结物的水溶性实验结果表明包结后格列本脲的溶解度增加了15倍。
Glibenclamide (glyburide) binds to sulphonylurea receptors, the regulatory subunit of ATP-sensitive K + channels prominently expressed in the ER.
格列本脲能结合磺脲受体，该受体是主要在ER中表达的AT P敏感的钾通道的调节亚基。
Conclusion the method is accurate and reliable with good reproducibility, which can be used for the content control of glibenclamide in Xiaokeping Capsules.
结论高效液相色谱法简便、准确，重现性好，可用于控制消渴平胶囊中格列苯脲的含量。
Furthermore, hypothalamic dominant-negative Kir6.2 expression or the delivery of the KATP channel blocker glibenclamide abolished the glucose production-lowering effects of OAG.
此外，下丘脑显性负相Kir2的表达或使用KATP通道阻滞剂格列本脲能抵消oag的作用减少葡萄糖生成的作用。
BACKGROUND: Aim of the present study is the comparison of all-cause, cardioascular and non-cardioascular mortality, and cardiac morbidity, between patients treated with glibenclamide and gliclazide.
研究背景：现状研究的目的是比较服用格列苯脲和格列齐特患者之间全造成的心血管与非心血管病死亡率、心血管病发病率。
BACKGROUND: Aim of the present study is the comparison of all-cause, cardioascular and non-cardioascular mortality, and cardiac morbidity, between patients treated with glibenclamide and gliclazide.
研究背景：现状研究的目的是比较服用格列苯脲和格列齐特患者之间全造成的心血管与非心血管病死亡率、心血管病发病率。
应用推荐